Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q14995
UPID:
NR1D2_HUMAN
Alternative names:
Orphan nuclear hormone receptor BD73; Rev-erb alpha-related receptor; Rev-erb-beta; V-erbA-related protein 1-related
Alternative UPACC:
Q14995; B2R8Q3; O00402; Q86XD4
Background:
Nuclear receptor subfamily 1 group D member 2, also known as Rev-erb alpha-related receptor, plays a pivotal role in regulating circadian rhythm and metabolic pathways. It acts as a transcriptional repressor, influencing the expression of core clock components and genes involved in lipid metabolism and the inflammatory response. Its function is modulated by heme, enhancing its interaction with the NCOR1/HDAC3 corepressor complex.
Therapeutic significance:
Understanding the role of Nuclear receptor subfamily 1 group D member 2 could open doors to potential therapeutic strategies.